JP2016535732A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535732A5
JP2016535732A5 JP2016525875A JP2016525875A JP2016535732A5 JP 2016535732 A5 JP2016535732 A5 JP 2016535732A5 JP 2016525875 A JP2016525875 A JP 2016525875A JP 2016525875 A JP2016525875 A JP 2016525875A JP 2016535732 A5 JP2016535732 A5 JP 2016535732A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
heteroaryl
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016525875A
Other languages
English (en)
Japanese (ja)
Other versions
JP6466433B2 (ja
JP2016535732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061870 external-priority patent/WO2015061518A1/en
Publication of JP2016535732A publication Critical patent/JP2016535732A/ja
Publication of JP2016535732A5 publication Critical patent/JP2016535732A5/ja
Application granted granted Critical
Publication of JP6466433B2 publication Critical patent/JP6466433B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016525875A 2013-10-24 2014-10-23 ヒト免疫不全ウイルス複製の阻害剤 Expired - Fee Related JP6466433B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895102P 2013-10-24 2013-10-24
US61/895,102 2013-10-24
PCT/US2014/061870 WO2015061518A1 (en) 2013-10-24 2014-10-23 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2016535732A JP2016535732A (ja) 2016-11-17
JP2016535732A5 true JP2016535732A5 (enExample) 2017-07-13
JP6466433B2 JP6466433B2 (ja) 2019-02-06

Family

ID=51905392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525875A Expired - Fee Related JP6466433B2 (ja) 2013-10-24 2014-10-23 ヒト免疫不全ウイルス複製の阻害剤

Country Status (12)

Country Link
US (1) US10035760B2 (enExample)
EP (1) EP3060554A1 (enExample)
JP (1) JP6466433B2 (enExample)
KR (1) KR20160078382A (enExample)
CN (1) CN106458940A (enExample)
AU (1) AU2014340110B2 (enExample)
CA (1) CA2928541A1 (enExample)
EA (1) EA029259B1 (enExample)
IL (1) IL245213A0 (enExample)
MX (1) MX2016004492A (enExample)
SG (1) SG11201603217SA (enExample)
WO (1) WO2015061518A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
TW202138365A (zh) 2016-08-19 2021-10-16 美商基利科學股份有限公司 治療性化合物
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
TWI745652B (zh) 2018-02-16 2021-11-11 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
EP4643882A3 (en) 2019-11-26 2026-01-14 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
WO2021176367A1 (en) 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7520162B2 (ja) 2020-06-25 2024-07-22 ギリアード サイエンシーズ, インコーポレイテッド Hivの治療のためのカプシド阻害剤
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PT4440702T (pt) 2021-12-03 2025-08-13 Gilead Sciences Inc Compostos terapêuticos para a infecção pelo vírus do hiv
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ, インコーポレイテッド Hivウイルス感染症のための治療化合物
WO2024200331A2 (de) 2023-03-29 2024-10-03 Bayer Aktiengesellschaft Verfahren zur herstellung von methyl-4-isocyanatosulfonyl-5-methyl-thiophene-3-carboxylat
EP4727909A1 (en) 2023-06-15 2026-04-22 VIIV Healthcare UK (No.5) Limited Methods and intermediates for preparing compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272175A (en) * 1992-05-20 1993-12-21 G. D. Searle & Co. Substituted tyrosyl diamide compounds
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US20020045231A1 (en) * 1999-02-02 2002-04-18 Napper Andrew D. Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
EA200100972A1 (ru) * 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
WO2006005941A1 (en) * 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof

Similar Documents

Publication Publication Date Title
JP2013544261A5 (enExample)
JP2014506599A5 (enExample)
JP2014508811A5 (enExample)
JP2013537203A5 (enExample)
JP2014525432A5 (enExample)
JP2013538802A5 (enExample)
RU2017123114A (ru) 3-оксо-3-(ариламино)пропионаты, способ их получения и их применение в получении пирролидинонов
JP2017538689A5 (enExample)
JP2016506960A5 (enExample)
JP2012522847A5 (enExample)
JP2017533968A5 (enExample)
HRP20161541T1 (hr) Fuzionirani biciklični oksazolidinon kao inhibitor cetp
JP2015535839A5 (enExample)
JP2016520064A5 (enExample)
JP2013543842A5 (enExample)
JP2016505619A5 (enExample)
JP2020527175A5 (enExample)
ME02892B (me) Hemijska jedinjenja
JP2013531029A5 (enExample)
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
JP2016540742A5 (enExample)
JP2013510124A5 (enExample)
JP2009534358A5 (enExample)
JP2013542261A5 (enExample)
UA115881C2 (uk) Алкоксипіразоли як активатори розчинної гуанілатциклази